Patents by Inventor Philip F. Von Voigtlander

Philip F. Von Voigtlander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatments for nervous disorders
    Publication number: 20030232829
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: April 28, 2003
    Publication date: December 18, 2003
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Treatments for nervous disorders
    Patent number: 6586427
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 1, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Method for preventing or the progression of neuronal damage with pramipexole as a neuroprotective agent
    Patent number: 6458820
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: October 1, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Use of pramipexole for the treatment of addictive disorders
    Patent number: 6410579
    Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: June 25, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
  • Reboxetine for treatment obsessive compulsive disorders and panic disorder
    Patent number: 6391876
    Abstract: This invention relates to the use of reboxetine in the treatment of Obsessive Compulsive Disorders and Panic Disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: May 21, 2002
    Assignee: Pharmacia and Upjohn Company
    Inventors: Adriana Dubini, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • New treatments for nervous disorders
    Publication number: 20020049230
    Abstract: This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: August 13, 2001
    Publication date: April 25, 2002
    Applicant: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Treatments for nervous disorders
    Patent number: 6352986
    Abstract: This patent application describes the treatment of Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: March 5, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Fred Hassan, John Michael McCall, Duncan Paul Taylor, Philip F. Von Voigtlander, Erik Ho Fong Wong
  • Use of pramipexole for the treatment of addictive disorders
    Publication number: 20010041727
    Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: February 14, 2001
    Publication date: November 15, 2001
    Inventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
  • Use of pramipexole as a neuroprotective agent
    Patent number: 6156777
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: December 5, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Edward Dallas Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Pramipexole as a neuroprotective agent
    Patent number: 5650420
    Abstract: The present invention provides the use of pramipexole as a neuroprotective agent.
    Type: Grant
    Filed: December 15, 1994
    Date of Patent: July 22, 1997
    Assignees: Pharmacia & Upjohn Company, Boehringer Ingelheim International GmbH
    Inventors: Edward D. Hall, Philip F. Von Voigtlander, Frank A. Rohde
  • Trans-(+)-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]a c
    Patent number: 4663335
    Abstract: The trans(+)-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]a cetamide enantiomer, and salts thereof, have been found to be useful as Central Nervous System anti-seizure drugs, at reasonable dosages in warm-blooded animal patients, including humans, as determined in a standard anti-convulsant laboratory animal tests.
    Type: Grant
    Filed: October 25, 1985
    Date of Patent: May 5, 1987
    Assignee: The Upjohn Company
    Inventor: Philip F. Von Voigtlander
  • Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
    Patent number: 4463013
    Abstract: Conditions of inappropriate hyperhydration in warm blooded animals can be treated with an essentially water only diuretic drug compound selected from the group ##STR1## wherein m, n, p, A, E, R, R.sub.1, R.sub.2, X, Y and Z are as defined in the specification, e.g., trans-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]dec-8 -yl]benzeneacetamide, or a pharmaceutically acceptable salt thereof, ##STR2## wherein R, R.sub.1, R.sub.2, R.sub.3, P, Q, X and Y are as defined in the specification, e.g., 3,4-dichloro-N-[[8-(1-pyrrolidinyl)-1,4-dioxaspiro[4.5]-dec-8-yl]methyl]be nzeneacetamide, or a pharmaceutically acceptable salt thereof, or ##STR3## where R, R.sup.1, R.sup.2, X and Y are as defined in the specification, e.g., trans-(1)-2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] acetamide,or ##STR4## wherein p, n, q, X, Y, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, E, R.sub.5, R.sub.6 are as defined in the specification,or ##STR5## wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.
    Type: Grant
    Filed: August 18, 1982
    Date of Patent: July 31, 1984
    Assignee: The Upjohn Company
    Inventors: Robert J. Collins, Lester J. Kaplan, James H. Ludens, Philip F. Von Voigtlander